GSK says study shows cabotegravir can be dosed at four months

GSK said ViiV Healthcare, which is company majority owned by GSK, announced positive findings from its Phase I study showing that an investigational formulation of cabotegravir, known as cabotegravir ultra long-acting, can be dosed at intervals of at least four months. “This is the company’s first step towards delivering ultra long-acting injectable HIV treatment and prevention medicines that would potentially enable people to have at least four months between visits to the clinic,” GSK said in a statement. Data also showed that the intramuscular dosing of cabotegravir ultra long-acting has a safety and pharmacokinetic profile that supports a longer dose interval, the company added.